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Abstract We have cloned and sequenced the first 1.2 kb of the 
5' region of the human glucose-6-phosphatase gene. Transfection 
of H4IIE hepatoma cells with the 1.2 kb fragment fused to a 
luciferase reporter gene demonstrated both basal and hormone 
responsive luciferase activity. Dexamethasone increased and 
insulin decreased luciferase activity. Insulin and dibutyryl cyclic 
AMP both significantly decreased activity in the presence of 
de gamethasone. 
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In ~ulin; Gene regulation; cAMP 
1. Introduction 
Glucose-6-phosphatase [EC 3.1.3.9] catalyses the hydrolysis 
ol glucose-6-phosphate to glucose [1,2]. This reaction is the 
terminal step of both gluconeogenesis and glycogen break- 
down in liver. The importance of glucose-6-phosphatase to 
bl,~od glucose homeostasis  demonstrated by glycogen stor- 
age disease type la which is a severe metabolic disorder 
ca ased by a deficiency of the glucose-6-phosphatase enzyme 
[3. Due to its physiological function the enzyme is predomi- 
ni~ntly expressed in liver and kidney where it is tightly asso- 
ci~ted with the membrane of the endoplasmic reticulum. The 
active site of the glucose-6-phosphatase enzyme is inside the 
lunen of the endoplasmic reticulum and the enzyme is part of 
a multicomponent system which also consists of transport 
proteins for the substrate glucose-6-phosphate nd the prod- 
ucts glucose and phosphate [2,4]. 
l'here are three substrate cycles in the liver gluconeogenic 
al~d glycolytic pathways and the direction of net flux through 
th~se cycles is controlled by the relative activities of phosphoe- 
m lpyruvate carboxykinase compared to pyruvate kinase; 
fructose-l,6-bisphosphatase compared to 6-phosphofructo-1- 
kJ lase and glucose-6-phosphatase compared to glucokinase. 
The gene regulation of five of these enzymes has been exten- 
si~ ely studied (phosphoenolpyruvate carboxykinase, pyruvate 
kJ lase, fructose-l,6-bisphosphatase, 6-phosphofructo-l-kinase 
ar d glucokinase; see [5] for a review). In contrast, much less is 
k~ own about glucose-6-phosphatase gene, RNA and protein 
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regulation. There are several reasons for the relative lack of 
knowledge about the regulation of glucose-6-phosphatase. 
The membrane association and instability in vitro delayed 
for a long time a molecular characterisation f the glucose- 
6-phosphatase enzyme protein [4] and the human glucose-6- 
phosphatase enzyme was cloned only recently [6,7]. Investiga- 
tion of the function and regulation of the glucose-6-phospha- 
tase enzyme in liver has also been greatly hampered by the 
lack of cell lines expressing significant levels of glucose-6- 
phosphatase activity. However, from animal studies it is clear 
that hepatic glucose-6-phosphatase is r gulated. Hepatic glu- 
cose-6-phosphatase enzyme activity [1,8], protein levels [8], 
and mRNA levels [9] all increase greatly in animal models 
of diabetes mellitus. Administration of glucocorticoids, insu- 
lin, thyroid hormone or glucagon to animals has been shown 
to alter glucose-6-phosphatase ctivity in microsomes [1,10- 
13]. In addition, liver glucose-6-phosphatase enzyme activity, 
protein and mRNA levels are developmentally regulated in 
mammals [9,14,15]. It therefore seems likely that a number 
of cis-acting elements will be present in the promoter egula- 
tory region of the glucose-6-phosphatase gene to confer these 
multiple modes of regulation but to date the 5' region of the 
gene has not been characterised and very little is known about 
the mechanisms of hormonal regulation of glucose-6-phos- 
phatase gene expression [16]. 
In this study we report the cloning and sequencing of the 5' 
region of the human glucose-6-phosphatase gene. The expres- 
sion in H4IIE hepatoma cells of a construct between the first 
1.2 kb of this region and a luciferase reporter gene was regu- 
lated by dexamethasone, insulin and dibutyryl cyclic AMP 
(dBcAMP). 
2. Materials and methods 
2.1. Materials 
Restriction endonucleases, modifying enzymes, plasmid DNA pur- 
ification kit (Wizard), and random prime labelling kit (Prime a Gene 
system) were from Promega. All radioisotopes for labelling probes 
([a-32p]dCTP) and sequencing ([~-35S]dATP) and Hybond N + were 
purchased from Amersham. Insulin, dibutyryl cAMP, dexamethasone 
were purchased from Sigma. Kodak Biomax MR Scientific Imaging 
Film was used for all autoradiography. 
2.2. Library screening 
Duplicate high density filters containing DNA from a human chro- 
mosome 17 specific genomic cosmid library (Reference Library, 
ICRF) were probed with a full length cDNA of the human glucose- 
6-phosphatase catalytic subunit [6]. Four positives were identified, two 
of which (c105H1083 and c105H03159) contained overlapping inserts 
of the glucose-6-phosphatase gene. A combination of restriction map- 
ping and Southern blotting was then used to identify overlapping 
fragments of the 5' region of the gene. Appropriate fragments were 
gel isolated and subcloned into the polylinker region of the plasmid 
pGem7(+) (Promega). Both strands of the recombinant plasmids were 
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sequenced by the dideoxy chain termination method [17] using the 
Sequenase Version 2.0 sequencing kit (USB) utilising the T7 and 
SP6 promoter primers. When necessary deletion mutants of the re- 
combinants were generated using exonuclease III (Erase-a-Base sys- 
tem, Promega). 
2.3. Construction of the reporter gene plasmids 
A 0.6 kb BamHI fragment (-498 to +114) of the promoter egion 
was cloned into the BamHI site of the pT7 Blue vector (Novagen). 
The 3' 57 bases (which code for the first 19 amino acids of the glu- 
cose-6-phosphatase protein) were deleted from this construct using 
exonuclease III. The remaining insert was cloned into the EcoRI/Hin- 
dill site of pGem7 and a 0.75 kb SacI/BamHI fragment of the 
c105H03159 cosmid was cloned upstream of this. This 1.25 kb insert 
was then cloned into the SacI/XhoI site of the pGL3 Basic vector 
(Promega). The reporter gene construct (pGL3-1.3) was verified by 
restriction mapping and sequencing. 
2.4. Cell culture and transient expression assays 
H4IIE cells were grown in DMEM (Dulbecco's modified Eagle's 
medium) supplemented with 10% foetal calf serum. One day before 
the transfection 600000 cells were plated out per culture dish (35 
mm). 4 h before the transfection the cells were fed with fresh culture 
medium. Transfection was performed with the CaPOJDNA co-pre- 
cipitation method according to Docherty and Clard [18], with the 
modification that per dish 250 gl of the precipitate was used contain- 
ing 10 gg DNA of the reporter gene and 1.5 lag pSV-I~-galactosidase 
control vector (Promega) as internal standard for the transcription 
efficiency. After 18 h the DNA-containing medium was replaced by 
DMEM/15% glycerol for 2 min [19]. Then the cells were washed and 
cultivated for 4 h in DMEM. Subsequently the medium was replaced 
by DMEM containing dexamethasone, insulin or dibutyryl cAMP. 46 
h after the transfection the cells were washed twice with phosphate- 
buffered saline and lysed with reporter lysis buffer. Luciferase activity 
was determined with a Bio-Orbit 1250 Luminometer (LKB) using the 
Luciferase Assay Reagent (Promega). 13-Galactosidase activity was 
determined at 420 nm with o-nitrophenyl L3-D-galactopyranoside as 
substrate [20]. Statistical analysis was performed using the InStat pro- 
gram (version 2.01) for Macintosh computers. 
3. Results and discussion 
The first 1.2 kb of the 5' region of the human glucose-6- 
phosphatase gene was isolated and sequenced in both direc- 
tions. The sequence obtained is shown in Fig. 1. The 5' pro- 
moter region of the glucose-6-phosphatase gene contained a 
perfect consensus equence for a TATA box. There are also a 
number of sequences with homologies to putative binding 
sites for liver enriched transcription factors within the 5' 
flanking region (Fig. 1). These include three C/EBP sites, an 
HNF 1, an HNF 3, an HNF 4 and five HNF 5 sites together 
with three binding sites for the general transcription AP-1 and 
two CRE sites and two IRE sites. In addition a weak putative 
GRE binding site was found at -332.  While many of the 
putative binding sites in the 5' promoter region of the glu- 
cose-6-phosphatase g ne may not of course be functional in 
vivo, the presence of so many sites could indicate that this 
might be a highly regulated portion of the 5' region of the 
gene. 
To determine if the sequenced region contained a functional 
promoter we constructed a reporter gene plasmid (pGL3-1.3) 
containing this portion of the glucose-6-phosphatase 5' region 
(-1227 to +57) and transfected it into H4IIE hepatoma cells. 
Transfection of plasmid pGL3-1.3 into H4IIE cells resulted in 
three-fold greater luciferase activity than cells transfected with 
basic vector (pGL3) alone (Table 1). It also demonstrated that 
this 5' region of the glucose-6-phosphatase gene does contain 
hormone response elements as it was regulated by the syn- 
thetic glucocorticoid examethasone, the cAMP mimetic di- 
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butyryl cAMP and insulin (Table 1). Dexamethasone in- 
creased the luciferase activity in pGL3-1.3 transfected cells 
10-fold, insulin significantly decreased it to levels which were 
very similar to the basal expression of luciferase activity of the 
AP 2 
-1227 GAGCTCAGGA ATTCAAGACC AGCCTGGGCA ACATGGAAAA 
AP 2 
-1187 ACCCCATCTC TACAAAAGAT AGAAAA TTA GCCAGGCATG 
-1147 GTGGCGTGTG CCTGTGGTCC CAGCTACTCA GGAGGCTGAG 
AP 1 
-1107 GTGGGAGGAT CACATTAGCC CAGGAGGTTG AGGCTGCAGT 
AP 1 
-1067 GAGCCGTGAT TATGCCACTG CACTC CAGCC TGGGAGACAG 
-1027 AGTGAGACCC TGTTTCAAAA AAAAGAGAGA GAAAATTTAA 
HNF 5 
- 987 AAAAGAAAAC ~ACACCAAGG GCTGTAACTT TAAGGTCATT 
C/EBP  
- 947 AAATGAATTA ATCACTGCAT TCAAAAACGA TTACTTCTGG 
- 907 CCCTAAGAGA CATGAGGCCA ATACCAGGAA GGGGGTTGAT 
AP 2 
- 867 CTCCCAAACC AGAGGCAGAC CCTAGACTCT AATACAGTTA 
- 827 AGGAAAGACC AGCAAGATGA TAGTCCCCAA TACAATAGAA 
- 787 GTTACTATAT TTTATTTGTT GTTTTTCTTT TGTTTTGTTT 
HNF 3 
- 747 TGTTTTGTTT TGTTTTGTTT TAGAGACTGG GGTCTTGCTC 
- 707 GATTGCCCAG GCTGTAGTGC AGCGGTGGGA CAATAGCTCA 
C/EBP IRE 
- 667 CTGCAGACTC CAACTCCTGG GCTCAAGCAA TCCTCCTGCC 
- 627 TCAGCCTCCT GAATAGCTGG GACTACAAGG GTACACCATC 
HNF 5 
- 587 ACACACACCA AAACAATTTT  TTAAATTTTT  GTGTAGAAAC 
AP 2 
- 547 GAGGGTCTTG CTTTGTTGCC CAGGCTGGTC TCCAACTCCT 
IRE 
- 507 GGCTTCAAGG GATCCTCCCA CCTCAGCCTC CCAAATTGCT 
AP 1 HNF 5 
- 467 GGGATTACAG GTGTGAGCCA CCACAACCAG CCAGAACTTT 
C/EBP 
- 427 ACTAATTTTA AAATTAAGAA CTTAAAACTT GAATAGCTAG 
HNF 5 
- 387 AGCACCAAGA TTTTTCTTTG TCCCCAAATA AGTGCAGTTG 
CRE HNF 4 
- 347 CAGGCATAGA AAATCTGACA TCTTTGCAAG AATCATCGTG 
GRE 
- 307 GATGTAGACT CTGTCCTGTG TCTCTGGCCT GGTTTCGGGG 
AP 2 
- 267 ACCAGGAGGG CAGACCCTTG CACTGCCAAG AAGCATGCCA 
HNF I 
- 227 AAGTTAATCA TTGGCCCTGC TGAGTACATG GCCGATCAGG 
C/EBP 
- 187 CTGTTTTTGT GTGCCTGTTT TTCTATTTTA CGTAAATCAC 
- 147 CCTGAACATG TTTGCATCAA CCTACTGGTG ATGCACCTTT 
HNF 5 
-- 107 GATCAATACA TTTTAGACAA ACGTGGTTTT TGAGTCCAAA 
CRE 
67 GATCAGGGCT GGGTTGACCT ~a~ATACTGGA TACAGGGCA~ 
TATA-BOX 
27 ATAAAACAGG GGCAAGGCAC AGACTCATAG CAGAGCAATC 
CRE 
14 ACCACCAAGC CTGGAATAAC TGCAAGGGCT CTGCTGACAT 
54 CTTCCTGAGG TGCCAAGGAA ATGAGGATGG AGGAAGGAAT 
94GAATGTTCTC CATGACTTTG Gz14 
Fig. 1. The nucleotide sequence of the proximal promoter egion of 
the human glucose-6-phosphatase gene (-1227 to +114). Various 
putative response lement motifs are indicated above the nucleotide 
sequence. The transcription start site is at +1 and the translational 
start site at +80 [6]. The transcription start site is marked with an 
X and the TATA box is underlined. CRE = cAMP response le- 
ment; C/EBP = CCAAT/enhancer binding protein; GRE = gluco- 
corticoid response lement; HNF = hepatocyte nuclear factor; IR- 
E = insulin response lement. The reporter gene construct pGL3-1.3 
contains a fragment containing nucleotides -1227 to +57 of this se- 
quence. 
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Table 1 
Effect of dexamethasone, insulin and dibutyryl cAMP on the transcriptional activity of the 1.2 kb glucose-6-phosphatase promoter 
65 
Vector Mediator Relative luciferase activity (fold enhancement 
over pGL3 basic vector) 
p(iL3 basic vector none 1 
p( iL3-1.3 none 3.2 + 0.6 
pC ,L3-1.3 dibutyryl cAMP 3.6 + 0.8 
pl iL3-1.3 dexamethasone 38.7 + 7.9** 
pC rL3-1.3 insulin 1.3 + 0.4* 
pl iL3-1.3 dexamethasone+dibutyryl cAMP 8.3 _+ 0.8'* A 
pl iL3-1.3 dexamethasone+insulin 2.2 + 0.4 A + 
pl iL3-1.3 dibutyryl cAMP+insulin 2.4 + 0.3 + 
L ciferase activity was assayed 46 h after transfection of H4IIE cells with the pGL3-1.3 construct. 24 h before harvesting the cells were main- 
ta,ned under hormonal and intracellular mediator influence as described in the Table. The following concentrations were used: insulin, 500 
nM; dexamethasone, 1 /aM; dibutyryl cAMP, 500 gM. Luciferase activities were corrected for I~-galactosidase activities. The results are ex- 
pl ~ssed as fold stimulation compared to the luciferase activity measured after transfection with pGL3 basic vector, which was set as 1.0. All 
v~dues represent the mean (S.D.) of three independent experiments, which were all carried out in triplicate. 
*Significantly different from pGL3-1.3 alone *P < 0.01, **P < 0.005; A significantly different from pGL3-!.3 plus dexamethasone A p < 0.005; 
% ~gnificantly different from pGL3-1.3 plus insulin +P < 0.05. 
p~3L3 basic vector (Table 1). Insulin significantly decreased 
the stimulation of luciferase activity by dexamethasone. In 
ct,ntrast, dibutyryl cAMP alone did not significantly alter 
f ie luciferase activity in the pGL3-1.3 transfected H4IIE cells 
(q able 1) and it only had a significant effect when it was used 
i~ combination with either dexamethasone or insulin. Dibu- 
ty ryl cAMP and dexamethasone have previously been shown 
tt synergistically increase the expression of another key glu- 
c~,neogenic enzyme (phosphoenolpyruvate carboxykinase) [5]. 
II was therefore surprising that dibutyryl cAMP decreased 
b, ~th the stimulation of luciferase activity by dexamethasone 
aad the inhibition of luciferase activity by insulin (Table 1). 
~I ae regulation of the expression of the reporter gene construct 
("able 1) is consistent with the recent report, based on North- 
e~ n blots of FAO cell RNA, that dexamethasone increases 
g ucose-6-phosphatase mRNA levels and insulin decreases 
tt em [21]. There have been some reports in the literature in- 
d cating that glucocorticoids (dexamethasone) increase liver 
g ucose-6-phosphatase enzyme activity and others showing 
t lat  it does not (e.g. [1,12,14,22-27]). A simple explanation 
fi,r these apparently conflicting findings would be that the 
effect of dexamethasone also depends on the levels of other 
h )rmones like insulin and glucagon as illustrated in Table 1. 
In liver glucokinase catalyses the formation of glucose-6- 
p losphate which is the opposite reaction to that of glucose- 
6 phosphatase. The molecular mechanisms in the long-term 
cmtrol  of the glucose/glucose-6-phosphate substrate cycle 
dJring the switch between glycolysis and gluconeogenesis 
a "e unknown [16]. The transcription of the glucokinase gene 
i.~ stimulated by insulin and inhibited by glucagon [5,16]. The 
d tta presented here suggest hat during the switch between 
g ycolysis and gluconeogenesis insulin might act at the tran- 
s, riptional evel as the predominant regulator in the control of 
tire glucose/glucose-6-phosphate substrate cycle. 
Recently approximately 20 different mutations have been 
fi,und in the coding region of the human glucose-6-phosphat- 
a re gene in patients with glycogen storage disease type la, e.g. 
[" ]. However in about 17% of cases of glycogen storage dis- 
e tse type la no mutations were found in the coding region of 
ti~e glucose-6-phosphatase gene [7]. A possible explanation is
that some patients with glycogen storage disease type la have 
nmtations in the promoter egion of the gene. The sequence 
data in Fig. 1 will facilitate future studies to determine if some 
patients with glycogen storage disease type 1 a have mutations 
in the 5' region of the glucose-6-phosphatase gene. 
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